Sandra E. Burke

944 total citations
30 papers, 768 citations indexed

About

Sandra E. Burke is a scholar working on Cardiology and Cardiovascular Medicine, Hematology and Physiology. According to data from OpenAlex, Sandra E. Burke has authored 30 papers receiving a total of 768 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Cardiology and Cardiovascular Medicine, 8 papers in Hematology and 8 papers in Physiology. Recurrent topics in Sandra E. Burke's work include Nitric Oxide and Endothelin Effects (8 papers), Blood Coagulation and Thrombosis Mechanisms (7 papers) and Protease and Inhibitor Mechanisms (7 papers). Sandra E. Burke is often cited by papers focused on Nitric Oxide and Endothelin Effects (8 papers), Blood Coagulation and Thrombosis Mechanisms (7 papers) and Protease and Inhibitor Mechanisms (7 papers). Sandra E. Burke collaborates with scholars based in United States, United Kingdom and Germany. Sandra E. Burke's co-authors include Craig D. Wegner, Nathan L. Lubbers, Allan M. Lefer, J. Bryan Smith, Lewis B. Schwartz, Richard E. Kuntz, Terry J. Opgenorth, K. C. Nicolaou, Jerry L. Wessale and Bryan F. Cox and has published in prestigious journals such as Circulation, Advanced Drug Delivery Reviews and Journal of Medicinal Chemistry.

In The Last Decade

Sandra E. Burke

30 papers receiving 737 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sandra E. Burke United States 15 304 232 217 199 112 30 768
Arao Ujiie Japan 18 104 0.3× 123 0.5× 292 1.3× 145 0.7× 99 0.9× 51 870
Signe E. Varner United States 8 262 0.9× 263 1.1× 460 2.1× 122 0.6× 116 1.0× 14 1.1k
A Rosenkranz Germany 18 450 1.5× 85 0.4× 228 1.1× 147 0.7× 122 1.1× 54 791
Yuzo Matsumoto Japan 23 209 0.7× 183 0.8× 256 1.2× 88 0.4× 61 0.5× 73 1.3k
Jon Vincelette United States 15 228 0.8× 123 0.5× 205 0.9× 83 0.4× 134 1.2× 24 775
James K. Hennan United States 21 675 2.2× 123 0.5× 642 3.0× 117 0.6× 69 0.6× 45 1.4k
Céline Bouvet Canada 14 283 0.9× 119 0.5× 152 0.7× 130 0.7× 127 1.1× 15 807
R W Colman United States 20 316 1.0× 241 1.0× 265 1.2× 46 0.2× 125 1.1× 32 1.3k
Cathy Malcontenti‐Wilson Australia 16 95 0.3× 139 0.6× 250 1.2× 91 0.5× 81 0.7× 32 802
Heiko von der Leyen Germany 16 432 1.4× 127 0.5× 567 2.6× 176 0.9× 38 0.3× 38 1.1k

Countries citing papers authored by Sandra E. Burke

Since Specialization
Citations

This map shows the geographic impact of Sandra E. Burke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sandra E. Burke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sandra E. Burke more than expected).

Fields of papers citing papers by Sandra E. Burke

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sandra E. Burke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sandra E. Burke. The network helps show where Sandra E. Burke may publish in the future.

Co-authorship network of co-authors of Sandra E. Burke

This figure shows the co-authorship network connecting the top 25 collaborators of Sandra E. Burke. A scholar is included among the top collaborators of Sandra E. Burke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sandra E. Burke. Sandra E. Burke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
García‐Touchard, Arturo, et al.. (2006). Zotarolimus-eluting stents reduce experimental coronary artery neointimal hyperplasia after 4 weeks. European Heart Journal. 27(8). 988–993. 40 indexed citations
2.
Burke, Sandra E., Richard E. Kuntz, & Lewis B. Schwartz. (2006). Zotarolimus (ABT-578) eluting stents. Advanced Drug Delivery Reviews. 58(3). 437–446. 67 indexed citations
3.
Lubbers, Nathan L., James S. Polakowski, Craig D. Wegner, et al.. (2002). Oral bimoclomol elevates heat shock protein 70 and reduces myocardial infarct size in rats. European Journal of Pharmacology. 435(1). 79–83. 38 indexed citations
4.
Luo, Yanping, Vincent P. Hradil, Jerry L. Wessale, et al.. (2002). Evaluation of tissue perfusion in a rat model of hind‐limb muscle ischemia using dynamic contrast‐enhanced magnetic resonance imaging. Journal of Magnetic Resonance Imaging. 16(3). 277–283. 34 indexed citations
5.
Burke, Sandra E., Richard Alan Nelson, Nathan L. Lubbers, et al.. (2000). Evidence for Vasoconstriction Mediated by the Endothelin-B Receptor in Domestic Swine. Journal of Cardiovascular Pharmacology. 35(6). 838–844. 10 indexed citations
6.
Burke, Sandra E., Nathan L. Lubbers, Yung‐Wu Chen, et al.. (1999). Neointimal Formation After Balloon-Induced Vascular Injury in Yucatan Minipigs is Reduced by Oral Rapamycin. Journal of Cardiovascular Pharmacology. 33(6). 829–835. 80 indexed citations
7.
Burke, Sandra E., Nathan L. Lubbers, Gerard D. Gagné, et al.. (1997). Selective Antagonism of the ETA Receptor Reduces Neointimal Hyperplasia After Balloon-Induced Vascular Injury in Pigs. Journal of Cardiovascular Pharmacology. 30(1). 33–41. 50 indexed citations
8.
Burke, Sandra E. & Richard Alan Nelson. (1997). Endothelin-Receptor Antagonist FR 139317 Reduces Infarct Size in a Rabbit Model When Given Before, But Not After, Coronary Artery Occlusion. Journal of Cardiovascular Pharmacology. 29(1). 87–92. 12 indexed citations
9.
10.
Credo, R.B. & Sandra E. Burke. (1995). Fibrinolytic Mechanism, Biochemistry, and Preclinical Pharmacology of Recombinant Prourokinase. Journal of Vascular and Interventional Radiology. 6(6). 8S–18S. 6 indexed citations
11.
Badylak, Stephen F., Jack Henkin, Sandra E. Burke, & Arthur A. Sasahara. (1992). New Developments in Thrombolytic Therapy. Advances in pharmacology. 23. 227–262. 1 indexed citations
12.
Burke, Sandra E., et al.. (1992). Reduction of Canine Myocardial Infarct Size by CI-959, An Inhibitor of Inflammatory Cell Activation. Journal of Cardiovascular Pharmacology. 20(4). 619–629. 11 indexed citations
13.
Sircar, Ila, et al.. (1992). Synthesis and biological activity of 4-(diphenylmethyl)-.alpha.-[(4-quinolinyloxy)methyl]-1-piperazineethanol and related compounds. Journal of Medicinal Chemistry. 35(23). 4442–4449. 24 indexed citations
14.
Badylak, Stephen F., et al.. (1991). Enhancement of the thrombolytic efficacy of prourokinase by lys-plasminogen in a dog model of arterial thrombosis. Thrombosis Research. 62(3). 115–126. 12 indexed citations
15.
Badylak, Stephen F., et al.. (1991). The Beneficial Effect of Lys-Plasminogen upon the Thrombolytic Efficacy of Urokinase in a Dog Model of Peripheral Arterial Thrombosis. Pathophysiology of Haemostasis and Thrombosis. 21(5). 278–285. 8 indexed citations
16.
Voytik, Sherry L., et al.. (1990). The Protective Effect of Heparin in a Dog Model of Rethrombosis Following Pharmacologic Thrombolysis. Thrombosis and Haemostasis. 64(3). 438–444. 7 indexed citations
17.
18.
Burke, Sandra E., et al.. (1984). Continuous Measurements of ATP Secretion in Vivo. Pharmaceutical Research. 1(1). 40–43. 3 indexed citations
19.
Burke, Sandra E., David M. Roth, & Allan M. Lefer. (1983). Antagonism of platelet aggregation by 13-azaprostanoic acid in acute myocardial ischemia and sudden death. Thrombosis Research. 29(5). 473–488. 10 indexed citations
20.
Lefer, Allan M., Sandra E. Burke, & J. Bryan Smith. (1983). Role of thromboxanes and prostaglandin endoperoxides in the pathogenesis of eicosanoid induced sudden death. Thrombosis Research. 32(3). 311–320. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Arao Ujiie Breakdown of academic impact, for papers by Signe E. Varner Breakdown of academic impact, for papers by A Rosenkranz Breakdown of academic impact, for papers by Yuzo Matsumoto Breakdown of academic impact, for papers by Jon Vincelette Breakdown of academic impact, for papers by James K. Hennan Breakdown of academic impact, for papers by Céline Bouvet Breakdown of academic impact, for papers by R W Colman Breakdown of academic impact, for papers by Cathy Malcontenti‐Wilson Breakdown of academic impact, for papers by Heiko von der Leyen
Rankless by CCL
2026